Lundbeck Baffled After German Assessment Snub, Novo Also Hit Again
This article was originally published in Scrip
Germany's health technology assessment body the Institute for Quality and Efficiency in Healthcare (IQWiG) has concluded Novo Nordisk's new antidiabetic Xultophy (insulin degludec plus liraglutide) and H. Lundbeck's antidepressant Brintellix (vortioxetine) bring no additional benefits to clinical practice, raising concerns yet again about how it evaluates new medicines.
You may also be interested in...
Laura Soucek, one of In Vivo’s 2020 Rising Leaders, is hoping to take Barcelona-based start-up Peptomyc to the next level. The company is nearing the clinic with an inhibitor of the transcription factor Myc, which is involved in the regulation of cellular proliferation, but can also be a driver of cancer.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
With a candidate COVID-19 therapy in clinical development, the UK’s Synairgen has raised $101m on the UK’s AIM to support clinical studies and manufacturing plans.